Reuma. PT - the rheumatic diseases portuguese register

Acta Reumatologica Portuguesa

Volumn 36, Issue 1, 2011, Pages 45-56

  Canhão, Helena ^a   Faustino, Augusto ^b   Martins, Fernando ^c   Fonseca, João Eurico ^d  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

^c Sociedade Portuguesa de Reumatologia ^*  (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Biological therapies; Portuguese Society of Rheuma tology; Register; Reuma.pt; Rheumatic diseases

Indexed keywords

ADULT; ARTICLE; FEMALE; HUMAN; MALE; MIDDLE AGED; PORTUGAL; REGISTER; RHEUMATIC DISEASE;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PORTUGAL; REGISTRIES; RHEUMATIC DISEASES;

EID: 79955646931     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Silman A, Symmons D, Scott DGI, Griffiths I. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003; 62: 28-29.
2. Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005; 23: 205-207.
3. Listing J, Strangfeld A, Rau R et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther 2006; 8:R66 (doi:10.1186/ar1933).
4. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007; 57: 756-761.
5. Kremer JM. The CORRONA Database. Clin Exp Rheumatol 2005; 23: 172-177.
6. van Vollenhoven RF, Askling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol 2005; 23: 195-200.
7. Fonseca JE, Canhão H, Reis P, Jesus H, Pereira Silva JA, Branco J, Viana Queiroz M. [Protocol for Clinical Monitoring of Rheumatoid Arthritis (PMAR)]. December 2007 update (PMAR)]. Acta Reuma Port 2007; 32: 367-374.
8. Canhão H, Fonseca JE, Castelão W, Viana Queiroz M. [Protocol for clinical monitoring of ankylosing spondylitis (PMEA)]. Acta Reuma Port 2003; 28: 93--97.
9. Canhao H, Fonseca JE, Santos MJ, Gomes JA. [Protocol for clinical monitoring of juvenile idiopathic arthritis]. Acta Reumatol Port 2007; 32: 277-281.
10. Fonseca JE, Canhão H, Reis P et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update. Acta Reumatol Port 2010; 35: 95-98.
11. Fonseca JE, Silva JA, Canhão H et al. [Practical guide for the use of biotechnological therapies in Rheumatoid Arthritis] Acta Reumatol Port 2009; 34: 395-399.
12. Santos MJ, Fonseca JE, Canhao H et al. [Guidelines for prescribing and monitoring biologic therapies in juvenile idiopathic arthritis]. Acta Reumatol Port 2007; 32: 43-47.
13. SPR Consensus Group for Biological Therapies on Ankylosing Spondylitis. [Consensus for the use of anti-TNF agents in ankylosing spondylitis]. Acta Reumatol Port 2005; 30: 155-159.
14. Grupo de Estudos de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia. Análise de 376 doentes com artrite reumatóide submetidos a terapêutica biológica registados na base de dados de agentes biológicos da sociedade portuguesa de reumatologia. Acta Reumatol Port 2005; 30: 63-71.
15. Grupo de Consensos para as terapêuticas Biológicas na Espondilite Anquilosante da SPR. Análise de doentes com Espondilite Anquilosante submetidos a terapêutica biológica registados na base de dados de agentes biológicos da Sociedade Portuguesa de Reumatologia. Acta Reumatol Port 2005; 30: 253-256.
16. Cruz M, Branco J. Resultados em Mais de Um Ano de Terapêuticas Biológicas em Doentes com Artrite Reumatóide. Acta Reumatol Port 2002; 27: 80-89.
17. Cruz M, Fonseca JE, Branco J. Três anos de administração de etanercept e infliximab a doentes com artrite reumatóide refractária. Avaliação clínica e radiográfica e de segurança. Acta Reumatol Port 2004; 29: 21-32.
18. Pereira JP, Vieira M, Rodrigues A et al. [Safety evaluation of biological therapies in rheumatoid arthritis patients registered in BioRePortAR at Santa Maria Hospital]. Acta Reumatol Port 2010; 35: 51-52.
19. Campanilho-Marques R, Polido-Pereira J, Rodrigues A et al. BioRePortAP, an electronic clinical record coupled with a database: an example of its use in a single center. Acta Reumatol Port 2010; 35: 176-183.
20. Mourao AF, Rodrigues A, Vinagre F et al. Seven years of experience with biological treatment in juvenile idiopathic arthritis. Acta Reumatol Port 2010; 35: 63-64.
21. Fonseca JE, Lucas H, Canhão H et al. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update. Acta Reumatol Port 2008; 33: 77-85.
22. Fonseca JE, Canhao H, Silva C et al. [Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience]. Acta Reumatol Port 2006; 31: 247-253.